



**Disclaimer** Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada.

## Q4/FY 2013 Financial Summary for Investors and Analysts

### Merck KGaA, Darmstadt, Germany – Another strong year of delivery:

- **FY 2013 guidance delivered**
- **Stable sales of €10.7 bn due to organic growth in all divisions despite strong currency headwinds**
- **EBITDA pre at upper end of guidance, increase of 10% to €3,253 m**
- **EPS pre increased by 15% to €8.78**
- **Fit for 2018 accelerated: €325 m savings instead of planned €280 m**
- **Significant net financial debt reduction to now ~ €300 m**
- **Humira settlement leads to EBITDA pre reducing effect of ~€50m in 2014**
- **Underlying tax rate decreases to 23-25% going forward**
- **FY 2014 guidance: EBITDA pre on existing platform stable; slight organic sales growth**

### Overview Financials

#### Q4 2013 Overview

- Sales decline as organic improvement is more than offset by negative currency effects
- Adjusted EBITDA and EPS improve slightly on solid organic performance and tight cost management despite loss of royalty income
- Solid operating cash flow contains €200 m CTA\* funding
- Cash-generating nature of business portfolio drives net debt reduction
- Improvement of working capital due to ongoing tight management

#### YE 2013 Balance Sheet

- Significant net debt reduction despite €200 m CTA\* funding in Q4
- Improvement of financial profile led to rating upgrades: S&P to “A” and Moody’s to “A3” both with stable outlook

#### FY 2013 Cash flow Statement

- Higher profit after tax due to good operational business performance; prior year burdened by restructuring
- Changes in provisions contain cash-outs for restructuring and CTA\* funding of €200 m
- Other assets and liabilities decrease due to lower tax payments
- Operating cash flow strength continued
- Investing cash flow contains cash-in from Geneva HQ sale (€251 m)
- Financing cash flow increases due to lower bond repayments

\*CTA = Contractual Trust Arrangement

Merck KGaA, Darmstadt, Germany

Frankfurter Straße 250 · 64293 Darmstadt  
Phone +49 6151 72-0  
Fax +49 6151 72-2000

www.emdgroup.com

Corporation with General Partners  
Commercial Register AG Darmstadt HRB 6164  
Registered Office: Darmstadt  
Chairman of the Supervisory Board:  
Rolf Krebs

Executive Board  
and General Partners:

Karl-Ludwig Kley (Chairman),  
Kai Beckmann, Stefan Oschmann, Bernd Reckmann,  
Matthias Zachert

## Q4 2013 Business Overview

### Biopharmaceuticals

- **Solid operational performance despite FX headwinds and royalty income decrease**
- Sales deviation yoy: organic +4%, FX -7%
- Organic sales growth is more than offset by currency effects, leading to slight sales decline
- Ongoing good performance in Emerging Markets (CMC & GM\*) and Japan (Erbix) key driver of organic growth
- Rebif stable in Q4 despite competitive pressure; 7% price increase posted end of December 2013
- Erbix growing 8% organically supported by good trial data; label change preparations ongoing
- EBIT includes €127 m asset impairment for Humira settlement
- Despite lower royalties and FX headwinds margin improves as marketing and selling and R&D costs are well managed

### Consumer Health

- **Strong FX headwinds and softer cough & cold season weigh on business performance**
- Sales deviation yoy: organic +0%, FX -6%
- Q4 sales down yoy and sequentially after strong Q3, burdened by significant FX headwinds and flat organic performance
- Weak cough and cold season due to mild winter
- Healthy organic growth in Europe, especially Germany, Belgium and Poland
- Continued momentum of strategic brands like Femibion, but modest performance of Seven Seas products
- Despite a more moderate Q4 performance Consumer Health has shown a very solid yearly profitability upgrade

### Performance Materials

- **Reasonable performance amid strong FX headwinds and moderate destocking**
- Sales deviation yoy: organic -1%, FX -7%
- Sales decrease due to currency headwinds and further supply chain destocking in Liquid Crystals
- Customer intimacy and continuous innovation in PS-VA and IPS improve mix and expand market share
- Strongest yoy operational improvement in Pigments driven by restructuring and Xirallic performance
- Completion of savings program: €20 m realized by 2013; one year ahead of plan
- EBITDA pre softer amid FX headwinds and destocking

\*CMC & GM = Cardiometabolic Care and General Medicine

## Life Science

- **A strong finish of the year**
- Sales deviation yoy: organic +7%, FX -7%
- Stable sales as strong organic growth is offset by strong FX effects
- All regions except North America (U.S. sequestration) contribute to organic growth
- Some Q1 pre-buying cannot be excluded
- Process and Lab Solutions with ongoing good performance due to biopharma demand as well as price and volume uptakes
- Challenging currency effects are being mitigated by stringent cost control in nearly all functional cost categories
- EBITDA and margin increase on robust profitable growth

## 2014 Outlook:

### The Group:

- **EBITDA pre on existing platform stable**
- **Slight organic sales growth**

### Outlook by division:

#### Biopharmaceuticals

- Sales organically stable; EBITDA pre slightly lower
- Rebif: Continuous competitive pressure; volume decline
- Erbitux: Moderate organic growth
- Emerging Markets growth

#### Consumer Health

- Moderate organic sales growth; moderate EBITDA pre increase
- Transfer of Neurobion and Floratil to Consumer Health (+~€265 m sales and +~€100 m EBITDA pre)

#### Performance Materials

- Slight organic sales growth; EBITDA pre at best stable
- Slight growth in Pigments

#### Life Science

- Moderate organic sales growth; slight increase of EBITDA pre

## Additional financial guidance

- Humira settlement  
2014 EBITDA pre impact ~ -€50 m
- The Group royalty, license and commission income in 2015 ~€130 – 150 m
- Corporate EBITDA pre: around -€200 m
- Underlying tax rate: ~23% to 25%
- Biosimilars investment 2014: ~€100 m
- Capex on PPE and software: ~€500 m
- Hedging / USD assumption: 2014 and 2015 hedge ratio around 30% at EUR/USD ~1.30 – 1.35

## The Group Q4

€ m	Group			Serono			Consumer Health			Performance Materials			Millipore			Corporate/Others		
	Q4 2012	Q4 2013	% YoY	Q4 2012	Q4 2013	% YoY	Q4 2012	Q4 2013	% YoY	Q4 2012	Q4 2013	% YoY	Q4 2012	Q4 2013	% YoY	Q4 2012	Q4 2013	% YoY
Sales	2,712	2,636	-3%	1,522	1,485	-2%	121	114	-6%	416	383	-8%	653	654	0%			
<b>% organic</b>			<b>4%</b>			<b>4%</b>			<b>0%</b>			<b>-1%</b>			<b>7%</b>			
% FX			-7%			-7%			-6%			-7%			-7%			
% portfolio			0%			0%			0%			0%			0%			
EBIT	312	264	-15%	220	141	-36%	-17	11	n.m.	133	134	1%	31	51	66%	-55	-72	31%
Depreciation and amortization	359	462	29%	226	339	50%	13	2	-85%	37	21	-43%	81	95	17%	2	5	>100%
EBITDA	671	726	8%	446	480	8%	-3	13	n.m.	170	155	-9%	112	145	30%	-53	-67	27%
One-time items on EBITDA	119	69	-42%	60	20	-66%	23	1	-94%	19	11	-39%	32	22	-30%	-15	14	n.m.
<b>EBITDA (pre-one time items)</b>	<b>790</b>	<b>795</b>	<b>1%</b>	<b>506</b>	<b>500</b>	<b>-1%</b>	<b>20</b>	<b>15</b>	<b>-25%</b>	<b>188</b>	<b>167</b>	<b>-12%</b>	<b>143</b>	<b>168</b>	<b>17%</b>	<b>-68</b>	<b>-54</b>	<b>-21%</b>

## The Group FY

€ m	Group			Serono			Consumer Health			Performance Materials			Millipore			Corporate/Others		
	FY 2012	FY 2013	% YoY	FY 2012	FY 2013	% YoY	FY 2012	FY 2013	% YoY	FY 2012	FY 2013	% YoY	FY 2012	FY 2013	% YoY	FY 2012	FY 2013	% YoY
Sales	10,741	10,700	0%	5,996	5,954	-1%	473	477	1%	1,674	1,642	-2%	2,598	2,628	1%			
<b>% organic</b>			<b>4%</b>			<b>4%</b>			<b>6%</b>			<b>3%</b>			<b>6%</b>			
% FX			-5%			-5%			-5%			-5%			-5%			
% portfolio			0%			0%			0%			0%			1%			
EBIT	964	1,611	67%	548	893	63%	8	62	>100%	610	653	7%	252	262	4%	-453	-260	-43%
Depreciation and amortization	1,397	1,458	4%	932	993	7%	22	9	-60%	125	112	-10%	309	328	6%	8	16	94%
EBITDA	2,360	3,069	30%	1,480	1,886	27%	30	71	>100%	735	766	4%	561	590	5%	-445	-244	-45%
One-time items on EBITDA	605	184	-70%	345	69	-80%	37	1	-96%	7	14	89%	54	53	-1%	162	47	-71%
<b>EBITDA (pre-one time items)</b>	<b>2,965</b>	<b>3,253</b>	<b>10%</b>	<b>1,825</b>	<b>1,955</b>	<b>7%</b>	<b>67</b>	<b>72</b>	<b>8%</b>	<b>742</b>	<b>780</b>	<b>5%</b>	<b>614</b>	<b>643</b>	<b>5%</b>	<b>-283</b>	<b>-197</b>	<b>-30%</b>

Net financial debt\*

1,926 307 -84%

\* 2012 is Dec. 31

## The Group

P&L Group	Q4 2012	Q4 2013	% YoY
<b>Sales</b>	<b>2,712</b>	<b>2,636</b>	<b>-3%</b>
Royalty, license and commission income	123	105	-14%
Total revenues	2,835	2,742	-3%
Cost of sales	-814	-777	-4%
<b>Gross profit</b>	<b>2,021</b>	<b>1,965</b>	<b>-3%</b>
Marketing and selling expenses	-609	-582	-4%
Royalty and commission expenses	-146	-130	-11%
Administration	-132	-155	18%
Other operating income/expenses	-248	-291	17%
Research and development	-355	-345	-3%
Amortization of intangible assets	-220	-197	-10%
<b>EBIT</b>	<b>312</b>	<b>264</b>	<b>-15%</b>
Depreciation and amortization	359	462	29%
EBITDA	671	726	8%
One-time items on EBITDA	119	69	-42%
<b>EBITDA (pre-one time items)</b>	<b>790</b>	<b>795</b>	<b>1%</b>
Financial result	-61	-63	4%
<b>Profit before tax</b>	<b>251</b>	<b>201</b>	<b>-20%</b>
Income tax	25	80	>100%
Income tax rate	-10%	-40%	
Profit after tax	276	281	2%
Non-controlling interest	-4	-1	-79%
<b>Net income</b>	<b>272</b>	<b>281</b>	<b>3%</b>
Number of theoretical shares in million	217.4	217.4	
EPS in €	1.25	1.29	3%
EPS (pre one-time items) in €	2.05	2.12	3%

## Biopharmaceuticals

P&L MS	Q4 2012	Q4 2013	% YoY
<b>Sales</b>	<b>1,522</b>	<b>1,485</b>	<b>-2%</b>
Royalty, license and commission income	117	101	-14%
Total revenues	1,638	1,586	-3%
Cost of sales	-317	-307	-3%
<b>Gross profit</b>	<b>1,321</b>	<b>1,279</b>	<b>-3%</b>
Marketing and selling expenses	-341	-324	-5%
Royalty and commission expenses	-142	-125	-12%
Administration	-51	-57	12%
Other operating income/expenses	-132	-224	69%
Research and development	-271	-265	-2%
Amortization of intangible assets	-165	-143	-13%
<b>EBIT</b>	<b>220</b>	<b>141</b>	<b>-36%</b>
Depreciation and amortization	226	339	50%
<b>EBITDA</b>	<b>446</b>	<b>480</b>	<b>8%</b>
One-time items on EBITDA	60	20	-66%
<b>EBITDA (pre-one time items)</b>	<b>506</b>	<b>500</b>	<b>-1%</b>

## Consumer Health

P&L CH	Q4 2012	Q4 2013	% YoY
<b>Sales</b>	<b>121</b>	<b>114</b>	<b>-6%</b>
Royalty, license and commission income	1	1	-4%
Total revenues	122	115	-6%
Cost of sales	-43	-42	-2%
<b>Gross profit</b>	<b>80</b>	<b>73</b>	<b>-8%</b>
Marketing and selling expenses	-59	-54	-9%
Royalty, license and commission income	-1	-1	11%
Administration	-5	-5	6%
Other operating income/expenses	-25	3	n.m.
Research and development	-6	-5	-13%
Amortization of intangible assets	-1	-1	-23%
<b>EBIT</b>	<b>-17</b>	<b>11</b>	<b>n.m.</b>
Depreciation and amortization	13	2	-85%
<b>EBITDA</b>	<b>-3</b>	<b>13</b>	<b>n.m.</b>
One-time items on EBITDA	23	1	-94%
<b>EBITDA (pre-one time items)</b>	<b>20</b>	<b>15</b>	<b>-25%</b>

## Performance Materials

P&L PM	Q4 2012	Q4 2013	% YoY
<b>Sales</b>	<b>416</b>	<b>383</b>	<b>-8%</b>
Royalty, license and commission income	0	1	37%
Total revenues	416	384	-8%
Cost of sales	-172	-151	-12%
<b>Gross profit</b>	<b>244</b>	<b>233</b>	<b>-4%</b>
Marketing and selling expenses	-36	-33	-9%
Royalty and commission expenses	0	0	n.m.
Administration	-7	-6	-16%
Other operating income/expenses	-29	-19	-34%
Research and development	-35	-36	4%
Amortization of intangible assets	-3	-4	24%
<b>EBIT</b>	<b>133</b>	<b>134</b>	<b>1%</b>
Depreciation and amortization	37	21	-43%
<b>EBITDA</b>	<b>170</b>	<b>155</b>	<b>-9%</b>
One-time items on EBITDA	19	11	-39%
<b>EBITDA (pre-one time items)</b>	<b>188</b>	<b>167</b>	<b>-12%</b>

## Life Science

P&L MM	Q4 2012	Q4 2013	% YoY
<b>Sales</b>	<b>653</b>	<b>654</b>	<b>0%</b>
Royalty, license and commission income	5	3	-32%
Total revenues	658	657	0%
Cost of sales	-281	-276	-2%
<b>Gross profit</b>	<b>377</b>	<b>380</b>	<b>1%</b>
Marketing and selling expenses	-174	-169	-3%
Royalty and commission expenses	-4	-4	-10%
Administration	-23	-25	6%
Other operating income/expenses	-50	-45	-11%
Research and development	-44	-38	-12%
Amortization of intangible assets	-51	-49	-4%
<b>EBIT</b>	<b>31</b>	<b>51</b>	<b>66%</b>
Depreciation and amortization	81	95	17%
<b>EBITDA</b>	<b>112</b>	<b>145</b>	<b>30%</b>
One-time items on EBITDA	32	22	-30%
<b>EBITDA (pre-one time items)</b>	<b>143</b>	<b>168</b>	<b>17%</b>